Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;87(3):1150-1154.
doi: 10.1111/bcp.14482. Epub 2020 Aug 2.

Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin

Mary Kelly  1 , Ròisìn O'Connor  1   2 , Liam Townsend  2   3 , Miriam Coghlan  1 , Eileen Relihan  1 , Miriam Moriarty  1 , Bernard Carr  1 , Gail Melanophy  1 , Caitriona Doyle  2 , Ciaran Bannan  2   3 , Ruth O'Riordan  2 , Concepta Merry  2 , Susie Clarke  2 , Colm Bergin  2   3
Affiliations
Free article

Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin

Mary Kelly et al. Br J Clin Pharmacol. 2021 Mar.
Free article

Abstract

Aims: To assess clinical outcomes and adverse drug events in patients hospitalised with COVID-19 treated with off-label hydroxychloroquine (HCQ) and azithromycin (Az).

Methods: We performed a retrospective analysis of hospitalised patients who had a positive polymerase chain reaction test for SARS-CoV-2 and received HCQ plus Az or no targeted therapy. The primary end point was clinical improvement on day 7 defined as either hospital discharge or an improvement of 2 points on a 6-category ordinal scale. Secondary outcomes included mortality at day 28, intensive care admission, requirement for mechanical ventilation and incidence of adverse events.

Results: Data from a total of 134 patients were evaluated; 82 patients received HCQ/Az and 52 patients received no targeted therapy. Clinical improvement was seen in 26.8% of patients who received HCQ/Az but this was not significant. The rates of intensive care transfer and mechanical ventilation were higher in the treatment group, but these differences were not significant. Mortality at day 28 was significantly higher in the treatment group (P = .03). Hypoglycaemia elevated liver function tests and QT prolongation were monitored in both groups. The risk of QT prolongation was significantly higher in the treatment group. Treatment was stopped early in 6 (7.3%) patients due to adverse events.

Conclusion: Although patients who received HCQ/Az were more severely ill the administration of these repurposed drugs did not result in clinical improvement and was associated with a significant increase in toxicity. This descriptive study highlights the importance of monitoring all repurposed agents for adverse events.

Keywords: COVID-19; adverse drug events; azithromycin; clinical pharmacy; hydroxychloroquine; medication safety.

PubMed Disclaimer

References

REFERENCES

    1. World Health Organization (WHO). Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. WHO/2019-nCoV/clinical/2020.4. 13 March 2020. https://apps.who.int/iris/handle/10665/331446. [Accessed May 5. 2020].
    1. Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-1799.
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
    1. Health Protection Surveillance Centre (HPSC). Epidemiology of COVID-19 in Ireland. https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/casesin.... Accessed May 7. 2020.
    1. Jaffe S. Regulators split on antimalarials for COVID-19. Lancet. 2020;395(10231):1179. https://doi.org/10.1016/S0140-6736(20)30817-5

MeSH terms

LinkOut - more resources